Drug Trial Radar · NCT06685341
PK/PD Study of YZJ-1139
Last checked: Nov 20, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Mar 7, 2019
Primary completion
Apr 10, 2019
Study completion Nov 15, 2019
Sponsor
- Lead sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To determine the dose-response relationship of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses. Secondary Objective: To investigate the safety and tolerability of YZJ-1139 in young and elderly Chinese subjects after a single oral administration of different doses, and to compare it with zolpidem at clinical doses.
Conditions
- Insomnia
Interventions
YZJ-1139Drug
YZJ-1139
PlaceboDrug
Oral tablet
ZolpidemDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- AUCinf of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- AUClast of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Tmax of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- t1/2 of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- CL/F of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Vz/F of YZJ-1139、zolpidemTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Left and right saccade peak velocity (SPV) of Eye MovementsTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- left and right saccade accuracy rate (SacAcc) of Eye MovementsTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Left and right saccade eye movement response time (SacRT) of Eye MovementsTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Smooth eye movement to the left and right (Smooth) of Eye MovementsTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Body SwayTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Simple response time of Choice Reaction Time TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Simple response accuracy rate of Choice Reaction Time TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Selective response time of Choice Reaction Time TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Selective response accuracy rate of Choice Reaction Time TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- The average reaction time for correct responses of Digit Symbol Substitution TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- The number of correct responses of Digit Symbol Substitution TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- The average reaction time for incorrect responses of Digit Symbol Substitution TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- The number of incorrect responses of Digit Symbol Substitution TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- The number of non-responses of Digit Symbol Substitution TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Immediate recall of Word Recall TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Delayed recall of Word Recall TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
- Delayed recognition of Word Recall TestTime frame: From Day 1 to Day 2 post single dose;up to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.